DHEA

Dehydroepiandrosterone (DHEA) is a steroid hormone primarily produced in the adrenal cortex and is the most abundant steroid hormone in primates. Researchers primarily study DHEA for its potential roles in aging, cognitive function, and various health conditions, including adrenal insufficiency and menopausal symptoms. Key findings indicate that DHEA levels decline with age and may be associated with longevity, while clinical evidence suggests its neurosteroidal properties could have beneficial effects on mood and cognition. Additionally, studies have shown that intravaginal DHEA can improve sexual function in women experiencing menopausal symptoms, demonstrating its relevance in clinical settings. Current research continues to explore the pharmacological effects of DHEA and its metabolites, as well as their implications for various therapeutic applications.

Dehydroepiandrosterone (DHEA), also known as Prasterone or Intrarosa, is an endogenous steroid hormone primarily synthesized in the adrenal cortex. It belongs to the class of sex hormones and is the most abundant steroid hormone in primates. DHEA is also available in synthetic forms for therapeutic use. It is a precursor to both androgens and estrogens, making it a critical component in the synthesis of sex steroids. Researchers have observed that DHEA levels peak in early adulthood and decline with age, leading to its investigation as a potential 'anti-aging' hormone. DHEA plays significant roles in various physiological processes, including acting as a neurosteroid with potential neuroprotective, pro-cognitive, anxiolytic, and antidepressant effects. It is also involved in the modulation of the immune system and bone metabolism. Research has focused on its use in treating adrenal insufficiency, depression, systemic lupus erythematosus (SLE), and menopausal symptoms. The mechanism of action of DHEA involves conversion to active sex steroids and interaction with specific membrane receptors in various tissues, including endothelial cells, the heart, kidney, liver, and brain. Although a specific intranuclear receptor for DHEA has not been identified, its metabolites exert widespread effects on multiple organ systems. Pharmacokinetically, DHEA has a rapid clearance from the blood, with a metabolic clearance rate of approximately 2000 L/day, while its sulfate ester, DHEAS, is cleared more slowly. DHEA and DHEAS interconvert, and both can be metabolized to androstenedione, testosterone, and estrogens in peripheral tissues. Clinically, DHEA is used for treating adrenal insufficiency and improving bone mineral density in SLE patients on glucocorticoids. It is available as a dietary supplement in some countries, leading to concerns about misuse. The FDA has granted orphan drug status for its use in preventing bone loss in SLE, but further research is needed to fully establish its therapeutic potential.

DHEA acts by converting to active sex steroids such as androgens and estrogens, which then bind to their respective receptors to exert biological effects. It also interacts with specific membrane receptors in endothelial cells and other tissues, influencing processes like neuroprotection and immune modulation.

DHEA primarily acts through its conversion to sex steroids, which then bind to androgen and estrogen receptors, activating androgen receptor signaling and estrogen receptor signaling pathways. Additionally, DHEA has neurosteroidal properties and may interact with specific membrane receptors in various tissues, influencing processes such as neuroprotection, cognition, and mood regulation. The exact mechanisms and specific intranuclear receptors for DHEA remain unclear, indicating that further research is needed to fully elucidate its actions.

Current evidence is limited regarding the long-term safety and efficacy of DHEA supplementation in healthy elderly populations, particularly concerning its potential adverse effects on hormone-sensitive tumors. Further research is needed to clarify the mechanisms of action of DHEA in the central nervous system and its specific receptor interactions, as well as to investigate the effects of DHEA in diverse populations, including those with chronic conditions and different age groups. Additionally, larger randomized controlled trials are required to assess the impact of intravaginal DHEA on sexual function in women with a history of thrombosis or cardiovascular disease to establish comprehensive safety profiles.